Asset Details
Do you wish to reserve the book?
The Role and Therapeutic Targeting of CCR5 in Breast Cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The Role and Therapeutic Targeting of CCR5 in Breast Cancer
Do you wish to request the book?
The Role and Therapeutic Targeting of CCR5 in Breast Cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The Role and Therapeutic Targeting of CCR5 in Breast Cancer
2023
Overview
The G-protein-coupled receptor C-C chemokine receptor 5 (CCR5) functions as a co-receptor for the entry of HIV into immune cells. CCR5 binds promiscuously to a diverse array of ligands initiating cell signaling that includes guided migration. Although well known to be expressed on immune cells, recent studies have shown the induction of CCR5 on the surface of breast cancer epithelial cells. The function of CCR5 on breast cancer epithelial cells includes the induction of aberrant cell survival signaling and tropism towards chemo attractants. As CCR5 is not expressed on normal epithelium, the receptor provides a potential useful target for therapy. Inhibitors of CCR5 (CCR5i), either small molecules (maraviroc, vicriviroc) or humanized monoclonal antibodies (leronlimab) have shown anti-tumor and anti-metastatic properties in preclinical studies. In early clinical studies, reviewed herein, CCR5i have shown promising results and evidence for effects on both the tumor and the anti-tumor immune response. Current clinical studies have therefore included combination therapy approaches with checkpoint inhibitors.
Publisher
MDPI AG,MDPI
Subject
/ Breast Neoplasms - drug therapy
/ Breast Neoplasms - metabolism
/ Breast Neoplasms - pathology
/ CCR5
/ CCR5 Receptor Antagonists - pharmacology
/ CCR5 Receptor Antagonists - therapeutic use
/ Female
/ HIV
/ Human immunodeficiency virus
/ Humans
/ Immune checkpoint inhibitors
/ Kinases
/ Ligands
/ Melanoma
/ Methods
/ Proteins
/ Receptors, CCR5 - metabolism
/ Review
/ triple-negative breast cancer
/ Tropism
/ Tumors
